rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    INSM
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Chart of the Day: Insmed, a Rising Biotech Powerhouse With Significant Upside Potential

      Technical indicators show Insmed stock poised to gain 30% from current levels.

      Nov 17Barron'sINSM
      Insmed Sees BRINSUPRI Reaching $7 Billion in Peak Sales, Expects Cash-Flow Positive Year Ahead
      Nov 17Yahoo FinanceINSM
      The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and Madrigal
      Nov 11Yahoo FinanceBCRXINSMTGTX
      Here’s How Much You Would Have Made Owning Insmed Stock In The Last 5 Years
      Nov 10BenzingaINSM
      Insmed Stock: A Blockbuster Launch, Priced Ahead Of Its Own Guidance (NASDAQ:INSM)
      Nov 7Seeking AlphaINSM
      Insmed to Present at November and December 2026 Investor Conferences
      Nov 4Yahoo FinanceINSM
      Guggenheim cuts Insmed stock price target on model changes to $201
      Nov 2Investing.comINSM
      Insmed (INSM) Lifts Guidance After Earnings As Fair Value Debate Heats Up
      Oct 31Yahoo FinanceINSM
      Insmed (INSM) Begins BRINSUPRI Sales In Japan
      Oct 31Yahoo FinanceINSM
      INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance
      Oct 30Yahoo FinanceINSM
      Insmed Incorporated Q3 2026 Earnings Call Summary
      Oct 30Yahoo FinanceINSM
      Goldman Sachs reiterates Insmed stock rating on Brinsupri beat
      Oct 30Investing.comINSM
      Stifel cuts Insmed stock price target to $195 on OpEx outlook
      Oct 29Investing.comINSM
      Insmed Inc (INSM) Q3 2026 Earnings Call Highlights: Brinsupri Hits Blockbuster Status as ...
      Oct 29Yahoo FinanceINSM
      Insmed Soars 12% on $400 Million Brinsupri Quarter as U.S. Launch “Continues to Exceed Expectations”
      Oct 29Yahoo FinanceINSM
      What Insmed (INSM) Said on Its Q3 Earnings Call
      Oct 29Yahoo FinanceINSM
      Insmed Q3 2026 slides: BRINSUPRI hits blockbuster status
      Oct 29Investing.comINSM
      Huntington Ingalls, Crocs, Carvana, Insmed And Other Big Stocks Moving Higher On Thursday
      Oct 29BenzingaCROXINSMCVNAHII
      Insmed Q3 Net Loss Narrows; Revenue Rises
      Oct 29Yahoo FinanceINSM
      Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
      Oct 29Yahoo FinanceINSM
      Why is Insmed stock surging today?
      Oct 29Investing.comINSM
      Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
      Oct 29Yahoo FinanceINSM
      Insmed earnings missed by $0.07, revenue topped estimates
      Oct 29Investing.comINSM
      Insmed: Q3 Earnings Snapshot
      Oct 29Yahoo FinanceINSM
      Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
      Oct 29Yahoo FinanceINSM
      Insmed set to report earnings as Japan launch tests growth story
      Oct 28Investing.comINSM
      H.C. Wainwright reiterates Insmed stock rating on pipeline progress
      Oct 27Investing.comINSM
      $100 Invested In Insmed 15 Years Ago Would Be Worth This Much Today
      Oct 22BenzingaINSM
      Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
      Oct 22Yahoo FinanceINSM
      Top 3 Health Care Stocks That Could Blast Off In October
      Oct 21BenzingaAXSMINSM
      Insmed adds two directors with pharma leadership experience
      Oct 20Investing.comINSM
      Insmed Appoints Two New Directors to Its Board
      Oct 20Yahoo FinanceINSM
      Insmed launches bronchiectasis treatment in Japan
      Oct 19Investing.comINSM
      Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan
      Oct 19Yahoo FinanceINSM
      Insmed launches four phase 3 trials for lung disease therapy
      Oct 15Investing.comINSM
      Insmed to present respiratory portfolio data at medical conferences
      Oct 14Investing.comINSM
      Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
      Oct 14Yahoo FinanceINSM
      Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), ACADIA Pharmaceuticals (ACAD) and Insmed (INSM)

      Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.

      Oct 13The Globe and MailACADINSMPFE
      Insmed Shares Fall After Wolfe Research Downgrade
      Oct 12Yahoo FinanceINSM
      Truist previews biotech earnings with focus on Insmed, BridgeBio
      Oct 12Investing.comBBIOINSMTFC
      This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Insmed (NASDAQ:INSM)

      Analysts downgraded UWMC, ACT, ROIV, INSM; ACT’s target fell to $44.

      Oct 12BenzingaINSMMNDY
      BofA cuts Insmed stock price target on valuation concerns
      Oct 12Investing.comINSM
      Wolfe Research Downgrades Insmed to Peer Perform From Outperform
      Oct 12Yahoo FinanceINSM
      InvestingPro’s fair value spotted Insmed’s 47% drop 10 months early By Investing.com
      Oct 11Investing.comINSM
      UBS reiterates Insmed stock rating on Brinsupri sales outlook
      Oct 8Investing.comINSM
      Does Insmed (INSM) CFO Exit With Reaffirmed Guidance Clarify Or Complicate Its Growth Narrative?

      Insmed Incorporated announced that Chief Financial Officer Sara Bonstein will step down after the company reported its third-quarter 2026 results and reaffirmed its full-year 2026 revenue guidance for BRINSUPRI® (brensocatib) of US$1.25 billion to US$1.40 billion and for ARIKAYCE® of US$450 million to US$470 million. The combination of a planned CFO transition and reiterated product revenue guidance offers investors a clearer view of Insmed’s operational continuity during an important...

      Oct 8Yahoo FinanceINSM
      BMO Capital reiterates Insmed stock rating on CFO transition
      Oct 6Investing.comINSM
      Insmed CFO Transition Amid Reaffirmed 2026 Revenue Outlook

      Detailed price information for Insmed Inc (INSM-Q) from The Globe and Mail including charting and trades.

      Oct 6The Globe and MailINSM
      $100 Invested In Insmed 5 Years Ago Would Be Worth This Much Today - Insmed (NASDAQ:INSM)

      Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 17.45% on an annualized basis producing an average annual return of 29.54%. Currently, Insmed has a market capitalization of $22.80 billion.

      Oct 5BenzingaINSM
      Why is Insmed stock sliding today?
      Oct 5Investing.comINSM

      This is the newest page. Registered accounts read further back.